EpiVax Oncology To Present Latest Research On The Importance Of Identifying And Removing, Using Machine-Learning Based Advanced Computational Tools, Inhibitory Neoantigens From Therapeutic Cancer …

NEW YORK, March 25, 2019 /PRNewswire/ — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced that its abstract has been selected for an oral presentation, at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019, taking place on March 29th – April 3rd in Atlanta, Georgia. It will present data highlighting how inhibitory neoepitopes uncovered using advanced computational tools affect immune responses to therapeutic cancer vaccines. Ancer™ is a Superior Neoantigen Prediction Platform, Powered by Machine Learning Based Algorithms. Self-like Treg Cancer Neoepitopes Uncovered Using Ancer™. “While it is extremely important to select both Class I and Class II ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 6

Ähnlich Nachrichten